Tilray Brands (WBO:TLR2) EBIT: €-1,262.3 Mil (TTM As of Feb. 2026)


WBO:TLR2 Tilray Brands Inc WBO:TLR2
55 GF Score
Price €3.92
GF Value €10.82
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Tilray Brands EBIT?

Tilray Brands WBO:TLR2 -4.16% 55 EBIT is €-1,262.3 Mil as of Feb. 2026. GuruFocus rates WBO:TLR2 with a GF Score™ of 55/100 and a GF Value™ of €10.82 (Possible Value Trap). The stock has 5 warning signs investors should review.

Tilray Brands's earnings before interest and taxes (EBIT) for the three months ended in Feb. 2026 was €-15.5 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Feb. 2026 was €-1,262.3 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Tilray Brands's annualized ROC % for the quarter that ended in Feb. 2026 was -4.90%. Tilray Brands's annualized ROC (Joel Greenblatt) % for the quarter that ended in Feb. 2026 was -8.95%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Tilray Brands's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Feb. 2026 was -236.76%.


Tilray Brands  (WBO:TLR2) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Tilray Brands's annualized ROC % for the quarter that ended in Feb. 2026 is calculated as:

ROC % (Q: Feb. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Nov. 2025 ) + Invested Capital (Q: Feb. 2026 ))/ count )
=-67.236 * ( 1 - 0% )/( (1367.241 + 1379.652)/ 2 )
=-67.236/1373.4465
=-4.90 %

where

Invested Capital(Q: Nov. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1815.288 - 195.855 - ( 252.192 - max(0, 224.307 - 630.859+252.192))
=1367.241

Invested Capital(Q: Feb. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1755.215 - 189.501 - ( 186.062 - max(0, 217.881 - 608.071+186.062))
=1379.652

Note: The Operating Income data used here is four times the quarterly (Feb. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Tilray Brands's annualized ROC (Joel Greenblatt) % for the quarter that ended in Feb. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Feb. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Nov. 2025  Q: Feb. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-61.908/( ( (492.966 + max(182.812, 0)) + (474.561 + max(232.508, 0)) )/ 2 )
=-61.908/( ( 675.778 + 707.069 )/ 2 )
=-61.908/691.4235
=-8.95 %

where Working Capital is:

Working Capital(Q: Nov. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(94.346 + 244.966 + 39.355) - (195.855 + 0 + 0)
=182.812

Working Capital(Q: Feb. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(100.143 + 247.288 + 74.578) - (189.501 + 0 + 0)
=232.508

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Feb. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Tilray Brands's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Feb. 2026 )
=-1262.32/533.157
=-236.76 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tilray Brands EBIT Related Terms


Tilray Brands EBIT Historical Data

* Premium members only.

The historical data trend for Tilray Brands's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tilray Brands EBIT Chart

Tilray Brands Annual Data
Trend May16 May17 May18 May19 May20 May21 May22 May23 May24 May25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -258.49 -379.34 -1,291.28 -184.77 -2,005.54

Tilray Brands Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -752.60 -1,222.01 5.09 -29.92 -15.48

WBO:TLR2 vs IRWD, BIOA, ESPR: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Tilray Brands's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tilray Brands EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tilray Brands's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Tilray Brands's EV-to-EBIT falls into.


WBO:TLR2
55GF Score
Tilray Brands Inc WBO:TLR2
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tilray Brands EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1,262.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €-1,262.3 Mil mean?
Tilray Brands (WBO:TLR2) has a EBIT of €-1,262.3 Mil as of Feb. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Tilray Brands.
Is Tilray Brands' EBIT too high?
Tilray Brands' current EBIT is €-1,262.3 Mil. Overall, Tilray Brands has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Tilray Brands' EBIT compare to IRWD and BIOA?
Tilray Brands' EBIT of €-1,262.3 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Tilray Brands. Tilray Brands's current EBIT is €-1,262.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tilray Brands stock overvalued right now?
Based on GuruFocus' analysis, Tilray Brands (WBO:TLR2) is currently considered Possible Value Trap. The stock's GF Value™ is €10.82, compared to a current price of €3.92 — trading 63.8% below its estimated fair value. The current EBIT is €-1,262.3 Mil. Tilray Brands' overall GF Score™ is 55/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Tilray Brands (WBO:TLR2), the current EBIT is €-1,262.3 Mil as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tilray Brands (WBO:TLR2) Overvalued in 2026?

Based on GuruFocus' analysis, Tilray Brands stock appears to be undervalued. The current stock price of €3.92 is trading 63.8% below its estimated GF Value™ of €10.82. GuruFocus considers Tilray Brands to be Possible Value Trap.

Key valuation signals for WBO:TLR2:

  • EBIT: €-1,262.3 Mil
  • GF Value™: €10.82 vs. price of €3.92 (63.8% below fair value)
  • GF Score™: 55/100 with 5 warning signs

No single metric tells the full story. See the WBO:TLR2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Tilray Brands Business Description

Address 265 Talbot Street West, Leamington, ON, CAN, N8H 5L4
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure comes mainly from alcohol.
55GF Score

Get the complete analysis for WBO:TLR2

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.92
Price
€10.82
GF Value